- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04276688
Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment
An Open-label Randomized Controlled Trial on Lopinavir/ Ritonavir, Ribavirin and Interferon Beta 1b Combination Versus Lopinavir/ Ritonavir Alone, as Treatment for 2019 Novel Coronavirus Infection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Hypothesis A combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b will expedite the recovery, suppress the viral load, shorten hospitalisation and reduce mortality in patients with 2019-n-CoV infection compared with to lopinavir/ ritonavir alone
Primary objective: To evaluate the safety and efficacy in mortality reduction with a combination of lopinavir/ ritonavir, ribavirin and interferon beta-1b in the treatment of patient hospitalised for 2019-n-CoV infection and compare this to lopinavir/ ritonavir alone
Subject/patient definition: Recruited subjects include adult patients ≥18 years of age, admitted to the HA Hospitals from February 2020 onwards, with laboratory confirmed 2019-n-CoV infection. All subjects give written informed consent. Subjects must be available to complete the study and comply with study procedures.
Study design: This is a prospective open-label randomised controlled trial among adult patients hospitalised after February 2020 for virologically confirmed 2019-n-CoV infection. Patients will be randomly assigned to either a 14-day course of lopinavir/ ritonavir 400mg/100mg twice daily, ribavirin 400mg bd and zero to three doses of subcutaneous injection of interferon beta-1b 1mL (0.25mg; 8 million IU) on day 1, 3 and 5 (depending on day of admission from symptoms onset) plus standard care, or a 14-day course of lopinavir/ ritonavir 400mg/100mg twice daily plus standard care alone (2:1).
Intervention/study article: lopinavir/ ritonavir, ribavirin and interferon beta-1b
Primary outcome: Time to negative nasopharyngeal swab (NPS) 2019-n-CoV coronavirus viral RT-PCR
Secondary outcome:
- Time to negative saliva 2019-n-CoV coronavirus viral RT-PCR
- Time to clinical improvement of NEWS2 (National Early Warning Score 2) of 0 maintained for 24 hours
- Length of hospitalisation
- Adverse events during treatment
- 30-day mortality
- Cytokine/ chemokine changes
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hong Kong, Hong Kong
- University of Hong Kong, Queen Mary Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recruited subjects include all adult patients ≥18 years hospitalised for virologically confirmed 2019-n-CoV infection.
- NEWS of ≥1 upon recruitment
- Auditory temperature ≥38°C with at least one of the following symptoms (cough, sputum production, sore-throat, nasal discharge, myalgia, headache or fatigue) upon admission
- Symptom duration ≤10 days
- All subjects give written informed consent.
- Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response.
Exclusion Criteria:
- Inability to comprehend and to follow all required study procedures.
- Allergy or severe reactions to the study drugs
- Patients with known prolonged QT or PR interval, second- or third-degree heart block, or ventricular cardiac arrhythmias, including torsade de pointes
- Patients taking medication that will potentially interact with lopinavir/ ritonavir, ribavirin or interferon-beta1b
- Patients with known history of severe depression
- Pregnant or lactation women
- Inability to comprehend and to follow all required study procedures
- Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study. Unwilling to refuse participation in another clinical study through the end of this study.
- Have a history of alcohol or drug abuse in the last 5 years.
- Have any condition that the investigator believes may interfere with successful completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Study group
triple combination
|
400mg/100mg twice daily for 14 days
400mg twice daily for 14 days
0.25mg subcutaneous injection alternate day for 3 days
|
Active Comparator: Control group
single
|
400mg/100mg twice daily for 14 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to negative NPS
Time Frame: Up to 1 month
|
Time to negative NPS 2019-n-CoV RT-PCR
|
Up to 1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time to negative saliva
Time Frame: Up to 1 month
|
Time to negative saliva 2019-n-CoV RT-PCR
|
Up to 1 month
|
Time to clinical improvement
Time Frame: Up to 1 month
|
Time to NEWS of 0
|
Up to 1 month
|
Hospitalisation
Time Frame: Up to 1 month
|
Length of hospitalisation
|
Up to 1 month
|
Mortality
Time Frame: Up to 1 month
|
30-day mortality
|
Up to 1 month
|
Immune reaction
Time Frame: up to 1 month
|
Cytokine/ chemokine changes
|
up to 1 month
|
Adverse events
Time Frame: up to 1 month
|
Adverse events during treatment
|
up to 1 month
|
Time to negative all clinical specimens
Time Frame: up to 1 month
|
Time to negative NPS, saliva, urine and stool 2019-n-CoV RT-PCR
|
up to 1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
General Publications
- Moschen AR. IBD in the time of corona - vigilance for immune-mediated diseases. Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):529-530. doi: 10.1038/s41575-020-0333-5.
- Hung IF, Lung KC, Tso EY, Liu R, Chung TW, Chu MY, Ng YY, Lo J, Chan J, Tam AR, Shum HP, Chan V, Wu AK, Sin KM, Leung WS, Law WL, Lung DC, Sin S, Yeung P, Yip CC, Zhang RR, Fung AY, Yan EY, Leung KH, Ip JD, Chu AW, Chan WM, Ng AC, Lee R, Fung K, Yeung A, Wu TC, Chan JW, Yan WW, Chan WM, Chan JF, Lie AK, Tsang OT, Cheng VC, Que TL, Lau CS, Chan KH, To KK, Yuen KY. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Coronavirus Infections
- Infections
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antimetabolites
- Antineoplastic Agents
- Immunologic Factors
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Adjuvants, Immunologic
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Interferons
- Ribavirin
- Ritonavir
- Lopinavir
- Interferon-beta
- Interferon beta-1b
Other Study ID Numbers
- UW-20-074
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Novel Coronavirus Infection
-
Affiliated Hospital to Academy of Military Medical...Beijing 302 HospitalUnknownNovel Coronavirus Infection PneumoniaChina
-
AudibleHealth AI, Inc.Sunrise Research Institute; Analytical Solutions Group, Inc.; Kelley Medical... and other collaboratorsCompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV DiseaseUnited States
-
Leidos Life SciencesUnited States Department of DefenseActive, not recruitingCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
Leidos Life SciencesUnited States Department of DefenseWithdrawnCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV Infection
-
Leidos Life SciencesUnited States Department of DefenseTerminatedCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
Ruijin HospitalRecruiting2019 Novel Coronavirus InfectionChina
-
Shanghai Jiao Tong University School of MedicineUnknown2019 Novel Coronavirus InfectionChina
-
Chelsea and Westminster NHS Foundation TrustUnknownCOVID-19 | COVID-19 Infection | 2019 Novel Coronavirus InfectionUnited Kingdom
-
Chelsea and Westminster NHS Foundation TrustRecruitingCOVID-19 | Corona Virus Infection | Coronavirus | 2019 Novel Coronavirus Infection | 2019nCoVUnited Kingdom
-
Huilan ZhangUnknownPneumonia | Novel Coronavirus Pneumonia | PirfenidoneChina
Clinical Trials on Lopinavir/ritonavir
-
Drugs for Neglected DiseasesUniversity of Cape Town; Medecins Sans Frontieres, Netherlands; UBS Optimus Foundation and other collaboratorsCompletedAcquired Immunodeficiency Syndrome | TuberculosisSouth Africa
-
Oswaldo Cruz FoundationMinistry of Health, BrazilCompletedHIV Infections | PregnancyBrazil
-
GlaxoSmithKlineCompletedHepatitis CUnited States
-
AbbVie (prior sponsor, Abbott)Completed
-
University of California, San DiegoAbbottCompletedHIV InfectionUnited States
-
Fundacion SEIMC-GESIDAAbbottCompletedHIV Infections | HIV Infection | LipodystrophySpain
-
AbbottCompleted
-
Institut National de la Santé Et de la Recherche...FUJIFILM Toyama Chemical Co., Ltd.RecruitingInfectious Disease | PharmacologyFrance
-
University College, LondonLifeArcCompleted